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Introduction: Since the mid-1990s, highly active antiretroviral therapy (HAART) has   modified 
the clinical course of human immunodeficiency virus (HIV) infection, reducing the rate of disease 
progression, the incidence of opportunistic infections, and mortality. The authors of this paper 
performed an economic analysis to estimate the cost-effectiveness of the HAART regimens in 
Italy for managing HIV-infected patients according to national guidelines.
Patients and methods: The incremental cost-effectiveness analysis was carried out by 
means of a Markov model, which through a decision-analytic approach, made it possible to 
compare the studied antiretroviral regimens. The population considered in the model consisted 
of adult subjects with HIV who received antiretroviral HAART treatment for the first time. The 
population considered in the analysis reflects the patients’ characteristics according to one of 
the regional surveillance systems HIV/AIDS infection report currently operating in Italy. The 
analysis was carried out from the point of view of the Italian health care system. The considered 
outcome measures were quality-adjusted life years (QALYs) and direct health costs calculated 
for the year 2010. Both the outcomes (QALYs) and the costs were discounted by 3.5%. The 
time horizon adopted in the model was 10 years.
Results: The model shows, in terms of cost per gained QALY, single tablet regimen (STR) 
appeared to be the most cost-effective therapeutic choice (€22,017), followed by tenofovir 
(TDF) + lamivudine + efavirenz (EFV) (€24,526), and TDF/emtricitabine (FTC) + nevirapine 
(€26,416), and TDF + FTC + EFV (€26,558); the remaining strategies have an incremental cost-
effectiveness ratio (ICER) value varying from €28,000 to €41,000 per QALY. The sensitivity 
analysis on the main variables confirmed the validity of the base case scenario.
Conclusion: STR is the most cost-effective treatment strategy, compared with the other thera-
peutic regimens recommended by the Italian guidelines. All the ICER values of the various 
regimens considered by the Italian guidelines were lower than the threshold value of €50,000 
commonly accepted at the international level. The model developed represents a tool for policy 
makers and health care professionals to make short- and long-term cost projections and thus 
evaluate their impact on the available budgets for HIV patients.
Keywords: antiretroviral therapy regimens, single tablet regimens, STR, Markov model, 
quality-adjusted life years, QALYs, HAART
Introduction
According to UNAIDS, at the end of 2009, 33.3 million people worldwide were 
estimated to be living with human immunodeficiency virus (HIV) or acquired 
immunodeficiency syndrome (AIDS).1 In Italy, the surveillance of HIV/AIDS in the 
period 1985–2008 reported a total of 42,747 new HIV diagnoses. In 2007, there were 
2012 new HIV diagnoses, equivalent to an incidence of 6.7 per 100,000 residents.2 
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The   economic burden of HIV infection is well recognized 
all around the world.3,4 Its management involves the use 
of health care service for HIV treatment, the treatment of 
AIDS-associated symptoms and opportunistic infections, and 
other costs associated with morbidity/premature mortality of 
adult working patients. Since the mid-1990s, highly active 
antiretroviral therapy (HAART) has modified the clinical 
course of the HIV infection, reducing the rate of disease 
progression, the incidence of opportunistic infections, and 
mortality.5,6 This prolonged survival has changed HIV infec-
tion into a chronic disease.7 As a consequence, combination 
antiretroviral therapy has resulted in longer survival and a 
better quality of life for many HIV-infected patients.8 The cur-
rent therapeutic options available in Italy and Europe include 
more than 20 approved antiretroviral drugs divided into five 
classes: nucleoside/nucleotide reverse transcriptase inhibi-
tors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors, fusion or entry inhibitors, 
and integrase inhibitors (InI). Each of these groups attacks 
HIV in a different way. The most common drug regimen 
(as HAART) given to people beginning treatment usually 
consists of two NRTIs combined with either an NNRTI, or 
a “boosted” protease inhibitor, or an InI.9 Each drug varies 
greatly in terms of efficacy, resistance, pill burden, safety, and 
price. Considering the complexity of the disease, the Italian 
recommendations are invaluable in assisting physicians in 
electing the most favorable therapies. However, because HIV 
is a prolonged disease, the treatment of which may continue 
for many years, the need for regimens with potent antiviral 
activity, proven long-term safety, good adherence, and a low 
rate of antiviral resistance should also be evaluated in terms 
of lifetime costs. In a context of limited health care resources, 
pharmacoeconomic considerations are crucial to help policy 
makers make the most appropriate decisions on resource 
allocation. The authors of this paper therefore performed an 
economic analysis to estimate the cost-effectiveness of the 
HAART regimens in Italy for managing HIV-infected patients 
according to national guidelines.9 They also estimated the 
impact of the disease on the quality of life of patients.
Patients and methods
The purpose of this study was to determine the incremental 
cost-effectiveness ratio (ICER) per (quality-adjusted) year 
of life gained for therapeutic combinations (regimens) based 
on drugs recommended by the Italian guidelines for the first-
line treatment of patients with HIV .9 The incremental cost-
effectiveness analysis was carried out by means of a Markov 
model, which through a decision-analytic approach, made it 
possible to compare the studied antiretroviral regimens.10 The 
analysis was carried out from the point of view of the Italian 
health care service (Servizio Sanitario Nazionale [SSN]). 
The considered outcome measures were quality-adjusted 
life years (QALYs) and direct health costs calculated for the 
year 2011. Both the outcomes (QALYs) and the costs were 
discounted by 3.5%.11 The time horizon adopted in the model 
was 10 years. The antiretroviral regimens considered follow 
the latest Italian guidelines and represent the drug options 
that are more frequently used in the first-line treatment of 
patients with HIV .9 The population considered in the model 
consisted of adult subjects with HIV who received antiretro-
viral HAART treatment for the first time; this hypothetical 
cohort reflects the patient characteristics according to one of 
the regional surveillance systems HIV/AIDS infection report 
currently operating in Italy.12
Structure of the model
The Markov model simulates the quality of life and the costs 
for an HIV patient for 10 years, starting from the administra-
tion of the initial treatment, through 1-year cycles, based on 
the administered antiretroviral therapy.13 After entering the 
model and receiving one of the antiretroviral regimens, the 
patient can “move” through eight health states, defined by 
the CD4-cell count combined with the viremia levels (VL), 
one AIDS state and one death state (Figure 1).
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Figure 1 Structure of the Markov model.
Abbreviations: AIDS, acquired immunodeficiency syndrome; VL, viremia levels.
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The model assigned patients responding to the   antiretroviral 
therapy a viremia value lower than 50   copies, and allowed 
responders to move within the CD4   classification. In case 
of failure of the first-line treatment, the model presumed a 
viremia value .50 copies for the patients and CD4 values fol-
lowing the trend of the untreated   population.14   Nonresponders 
with a CD4 value ,200 were changed to the AIDS state; 
patients were changed to the death state depending on their 
CD4 class, as shown in Table 1, and also 25% of patients 
with full-blown AIDS.2 Finally, the model was completed 
with appropriate occurrence values to define probabilistic 
knots, and with precise cost estimates, in order to finalize 
the comparison, as described below. Modeling was under-
taken using Microsoft Excel 2010 (Microsoft Corporation, 
Redmond, WA).
Transition probabilities and outcomes
Tables 1 and 2 report the percentage distribution of patients 
considered in the model with respect to the CD4-cell count. 
The distribution draws on the observations on the HIV-AIDS 
infection situation in the Emilia Romagna region (epidemic 
update as of December 31, 2009). Table 3 shows the immu-
nologic responses for each of the therapeutic regimens 
studied, as indicated in the Italian guidelines, and reports 
the bibliographical references. When data were not avail-
able, it was assumed that the response remained constant 
at the last observed value by applying the last value carried 
forward technique.
To evaluate cost-effectiveness, the ICER was used. When 
the value of a new therapeutic option needs to be assessed, 
the ICER provides the additional resources that have to be 
used to achieve the additional benefit: ICER is the differ-
ence in cost divided by the difference in effect between two 
alternatives. In this analysis, the direct costs and effective-
ness of each regimen were compared with the direct costs 
and effectiveness of the disease natural history (absence of 
treatment).
The effectiveness indicators considered in this economic 
evaluation are the QALYs. Table 4 shows the utility values 
associated with the eight health states identified by the 
CD4-cell count. These values, published in the study by 
Simpson et al,13 were calculated by means of the EuroQol-5 
Dimensions (EQ-5D) questionnaire.29 The permanence in 
the disease state (CD4 and viremia) was adjusted for the 
corresponding utility and then combined for the average 
expected lifetime, with the purpose to evaluate the years of 
survival adjusted for the quality of life.30
Resource consumption and costs
The resource consumption associated with the patients con-
sidered in the model is linked with the administration of the 
antiretroviral regimens and with other direct health costs, 
such as hospitalizations, medical examinations, laboratory 
tests, and so on. Table 5 shows the average annual costs for 
each first-line regimen. Dosages were calculated based on 
the Italian and British guidelines;9,31 whereas the purchase 
costs of the pharmaceutical specialties were calculated 
based on the reimbursement price paid by the SSN, which 
takes into account the price updates effective from January 
1, 2011.32
For every health state defined by the CD4-cell count, an 
additional health cost associated with patients was assumed, 
including a further consumption of health resources due to 
hospitalization, day hospital, general practitioner and special-
ist examinations, laboratory tests, and diagnostic procedures. 
Costs were estimated based on the results of the research by 
Garattini et al33 (Table 6). The cost data stratified by CD4 
were then actualized to 2010.34,35
Table 1 Patient distribution based on CD4-cell count and viremia 
and mortality per health state13
CD4-cell count Viremia 
(VL)
HIV-linked  
mortality rate
.500 cells/μL ,50 0.40%
.500 cells/μL $50 0.40%
351–500 cells/μL ,50 0.40%
351–500 cells/μL $50 0.40%
201–350 cells/μL ,50 0.80%
201–350 cells/μL $50 0.80%
,200 cells/μL ,50 8.44%
,200 cells/μL $50 8.44%
Abbreviation: HIV, human immunodeficiency virus.
Table  2  Patient  distribution  based  on  CD4-cell  count  and 
viremia
CD4-cell count Viremia 
(VL)
% distribution  
of patientsa  
(base case)
% distribution   
of patientsb  
(sensitivity  
analysis)
.500 cells/μL ,50 12.98% 3.25%
.500 cells/μL $50 12.98% 3.25%
351–500 cells/μL ,50 12.98% 7.00%
351–500 cells/μL $50 12.98% 7.00%
201–350 cells/μL ,50 16.36% 18.75%
201–350 cells/μL $50 16.36% 18.75%
,200 cells/μL ,50 7.70% 21.00%
,200 cells/μL $50 7.70% 21.00%
Notes: aAdapted from HIV-AIDS infection situation in the Emilia Romagna region 
(epidemic update as of December 31, 2009)12; badapted from Gallant et al.15
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Sensitivity analysis
The sensitivity analysis verified the impact of a series of 
variations of the base case with a large influence on the 
obtained results.9 A series of univariate analyses were carried 
out on some parameters of the simulation model, such as: 
virological response, HIV-associated mortality rate, and the 
initial distribution of patients based on the CD4-cell count. In 
particular, the allotment of patients per CD4-cell count was 
varied based on the evidence of the study by Gallant et al36 
and simulated for hypothetical seriousness scenarios. Each 
parameter was varied with respect to its 95% confidence 
interval.
Results
Table 7 shows the average annual cost and the QALYs 
for a patient with HIV treated with each of the first-line 
antiretroviral regimens mentioned in the Italian guidelines. 
The simulation model shows that patients treated with a 
single tablet regimen (STR) (0.755 QALY/year) have a 
better quality of life, with a higher number of QALYs than 
with other therapeutic regimens, followed by tenofovir/
Table 3 Efficacy data: immunologic response per different treatment regimen
Treatment Response rate Source
Year
1 2 3 4 5 6 7 8 9 10
Atripla TDF/FTC + EFV  
(single tablet  
regimen)
80.00% 67.00% 64.00% 64.00% 64.00% 64.00% 64.00% 64.00% 64.00% 64.00% Gallant et al,15 
Pozniak et al,16 
Arribas et al17
Truvada +  
Sustiva
TDF/FTC + EFV 80.00% 67.00% 64.00% 64.00% 64.00% 64.00% 64.00% 64.00% 64.00% 64.00% Gallant et al,15 
Pozniak et al,16 
Arribas et al17
Truvada +  
Reyataz +  
Norvir
TDF/FTC + ATV/r 78.00% 74.00% 74.00% 74.00% 74.00% 74.00% 74.00% 74.00% 74.00% 74.00% Molina et al,18  
Molina et al19
Truvada +  
Viramune
TDF/FTC + NVP 66.80% 66.80% 66.80% 66.80% 66.80% 66.80% 66.80% 66.80% 66.80% 66.80% Soriano et al20
Truvada +  
Prezista +  
Norvir
TDF/FTC + DRV/r 79.00% 79.00% 79.00% 79.00% 79.00% 79.00% 79.00% 79.00% 79.00% 79.00% Mills et al21
Truvada +  
Kaletra +  
Norvir
TDF/FTC + LPV/r 76.00% 68.00% 68.00% 68.00% 68.00% 68.00% 68.00% 68.00% 68.00% 68.00% Molina et al,19  
Molina et al20
Truvada +  
Isentress
TDF/FTC + RAL 86.10% 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% Lennox et al,22 
Lennox et al23
Viread +  
Epivir +  
Sustiva
TDF + 3TC + EFV 76.30% 72.60% 69.70% 69.70% 69.70% 69.70% 69.70% 69.70% 69.70% 69.70% Gallant et al24
Kivexa +  
Sustiva
ABC/3TC + EFV 59.00% 59.00% 59.00% 59.00% 59.00% 59.00% 59.00% 59.00% 59.00% 59.00% Post et al25
Kivexa +  
Reyataz +  
Norvir
ABC/3TC + ATV/r 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% 81.00% Squires et al26
Kivexa +  
Kaletra +  
Norvir
ABC/3TC + LPV/r 68.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% Smith et al,27  
Pulido et al28
Note: Response rate refers to HIV RNA , 50 copies/mL.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; FTC, emtricitabine; LPV/r, 
ritonavir-boosted lopinavir; NVP, nevirapine; RAL, raltegravir; TDF, tenofovir.
Table 4 Utility values associated with the eight health states 
identified by the CD4-cell count13
CD4-cell count Viremia (VL) Utility
.500 cells/μL ,50 0.946
.500 cells/μL $50 0.946
351–500 cells/μL ,50 0.933
351–500 cells/μL $50 0.933
201–350 cells/μL ,50 0.931
201–350 cells/μL $50 0.931
,200 cells/μL ,50 0.830
,200 cells/μL $50 0.830
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emtricitabine (TDF/FTC) + raltegravir (0.735 QALY/year) 
and abacavir/lamivudine (ABC/3TC) + atazanavir/ritonavir 
(0.731 QALY/year). Table 7 shows the mean treatment cost 
for a patient with HIV based on the first-line antiretroviral 
regimen received. The TDF + 3TC + efavirenz (EFV) regi-
men (€8211) reveals a lower mean treatment cost, followed 
by TDF/FTC + nevirapine with €8231, ABC + 3TC + EFV 
with €8047, and TDF + FTC + EFV with €8551. Comparing 
the above mentioned costs and outcomes in incremental terms 
(ICER) with the no-treatment strategy, the STR appeared to 
be the most cost-effective therapeutic choice (€22,017), fol-
lowed by TDF + 3TC + EFV (€24,526), TDF/FTC + nevi-
rapine (€26,416), and TDF + FTC + EFV (€26,558); the 
remaining strategies have an ICER value varying from 
€28,000 to €41,000 per QALY.
The sensitivity analysis carried out on the main vari-
ables does not highlight significant variations with respect 
to the base case. For instance, including the discount rate 
(0%–5%) on costs and QALYs determines an increase of 
the ICER for all therapeutic regimens. On the other hand, it 
is worth noting that the cost per QALY decreases with the 
increase of the seriousness of the treated patient’s disease 
(CD4), showing that severe-illness patients can benefit the 
most (Table 8).
Discussion
The therapeutic success against HIV is mainly due to the 
results obtained by scientific research, which allow find-
ing drugs with a powerful antiviral activity. Since 1996, 
with the discovery of new classes of drugs and molecules 
which can thwart viral replication on various fronts, and 
especially with the introduction of combined therapies, the 
life expectancy and quality of life of people with HIV have 
enormously improved. Adding new antiretroviral STRs to 
conventional therapies can help physicians in the choice 
of the optimal treatment to administer HIV patients. Since 
STR is not the only available therapeutic alternative, it was 
deemed necessary to carry out a comparison with other 
antiretroviral regimens; therefore the analysis considered the 
regimens recommended, to a varying extent, by the Italian 
guidelines. The comparison was not limited to considering 
clinical effectiveness, but it also evaluated treatment costs. 
In particular, an incremental cost-effectiveness analysis was 
performed for each regimen, with respect to the no-treatment 
option, from the point of view of the Italian national health 
care system (SSN) and taking into account the national 
guidelines.9 Such comparisons were carried out with the help 
of a Markov decision model over a 10-year time horizon. 
The model estimated QALYs as outcomes and direct health 
costs (drugs, medical examinations, hospitalizations, tests, 
and so on) as costs; these costs were attributed a value based 
on prices and rates as of 2010.
Table  5  Average  annual  costs  for  each  first-line  therapeutic 
regimen35,36
Treatment Annual costs 
HAART treatment
TDF/FTC + EFV (single tablet regimen) €7226
TDF/FTC + EFV €7226
TDF/FTC + ATV/r €9016
TDF/FTC + NVP €6936
TDF/FTC + DRV/r €10,167
TDF/FTC + LPV/r €9294
TDF/FTC + RAL €13156
TDF + 3TC + EFV €6711
ABC/3TC + EFV €6776
ABC/3TC + ATV/r €8566
ABC/3TC + LPV/r €8844
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; 
DRV/r,  ritonavir-boosted  darunavir;  EFV,  efavirenz;  FTC,  emtricitabine;  LPV/r, 
ritonavir-boosted lopinavir; NVP, nevirapine; RAL, raltegravir; TDF, tenofovir.
Table 6 Average annual cost per patient and health state expressed in CD4 (excluding HAART cost)33
AIDS CD4+ , 200 201 , CD4+ , 500 CD4+ . 501
Hospitalization and therapy €2457 €771 €233 €43
Hospitalizations €2121 €674 €196 €39
Laboratory tests €149 €64 €19 €3
Diagnostic procedures €187 €33 €19 €0
Day hospital €6336 €2583 €2316 €1886
Accesses €6279 €2557 €2300 €1877
Medical visits €57 €25 €15 €9
Specialist examinations €314 €348 €319 €299
Laboratory tests (outpatients) €980 €950 €937 €859
Diagnostic procedures (outpatients) €137 €80 €21 €28
Total cost €10,225 €4732 €3827 €3115
Abbreviation: HAART, highly active antiretroviral therapy.
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The results of the simulation model show that in terms 
of cost per gained QALY, STR is the most cost-effective 
treatment strategy, compared with the other therapeutic regi-
mens recommended by the guidelines. All the ICER values 
of the various regimens considered by the Italian guidelines 
were lower than the threshold value of €50,000, commonly 
accepted at the international level.36 This value has the pur-
pose of expressing the willingness of the decision makers to 
pay in order to obtain additional health units, or the purpose 
of making new therapies available to citizens. Though no 
officially established threshold is available for Italy, it is worth 
noting that recent guidelines by the Italian Health Economics 
Association9 recommend that a threshold of €25,000–40,000 
be adopted. Other acceptable references of cost-effectiveness 
for the Italian context are €36,500 and €60,000 and have been 
calculated by two different authors.37,38
The favorable result of the STR is probably due to lit-
erature evidence showing a better adherence of the patients 
to STR, which determines an increase of the quality of life 
of patients with HIV .39 However, it is now recognized that 
low adherence to antiretroviral drugs is strictly linked to the 
therapeutic regimen failure40 and consequently to the indi-
cators of the HIV-disease progression, such as virological 
failure,41 insufficient immunologic reconstitution, the clinical 
progression of the disease, and lastly, death.42,43 Adherence to 
therapy is not only necessary to obtain a therapeutic result in 
patients starting a treatment, but also to maintain an effective 
viral suppression in the course of time.44
The sensitivity analysis on the main variables con-
firmed the validity of the base case. It is worth noting, in 
particular, that the increasing seriousness of the patients’ 
conditions (CD4-cell decrease) improves the incremental 
cost-effectiveness ratio with respect to the no-treatment 
strategy for all therapeutic regimens. This result is con-
sistent with the indications of the Italian and international 
guidelines, suggesting the maximum evidence of outcomes 
in the treatment of patients with CD4-cell levels lower than 
500.9,31 Furthermore, the results of this present study are in 
line with other pharmacoeconomic analyses, in particular 
with the study of Ravasio30 and with the more recent cost-
utility analysis.45,46 Also, the sensitivity analysis includes 
any reduction in price of drugs due to patent expiry. For 
example, with the assumption of a 3TC price reduction of 
50% included into the TDF + 3TC + EFV regimen, the most 
cost-effective strategy remains the STR.
This study has a few limitations, the most important of 
which concerns the quality of data entered into the model; 
parameters such as efficacy, for example, are based on stud-
ies with a limited time-frame and hence may be inadequate 
for modeling the treatment of a chronic disease for a longer 
time. Other important limitations regard the transition prob-
abilities, which were lacking in some cases and thus assumed 
to remain constant over time, and the utilities, which were 
derived from different literature sources and considered to 
be acceptable for an Italian population.47 These assumptions 
were necessary to simplify the model or to take account of 
incomplete data into literature sources.
In addition to these limitations, the final result should be 
interpreted taking into account some others constraints. One 
constraint could be the adoption of a long-term simulation 
model (10 years) to compare the three alternative regimens, 
which was built on the basis of clinical information (now 
Table 7 Results: costs, QALYs and ICER of the base case scenario (10-year horizon)
Strength and  
evidence  
Italian GL
Treatment Mean cost  
per patient
Mean QALYs  
per patient
Mean cost  
per QALYs
Delta  
cost
Delta  
QALYs
ICER 
QALYs
Untreated €3492 0.525 €6645      
A1 TDF/FTC + EFV  
(single tablet regimen)
€8551 0.755 €11,323 €5059 0.230 €22,017
A1 A1 TDF/FTC + EFV €8551 0.716 €11,944 €5059 0.190 €26,558
A1 A1 TDF/FTC + ATV/r €9479 0.722 €13,124 €5988 0.197 €30,412
A1 B1 TDF/FTC + NVP €8231 0.705 €11,678 €4740 0.179 €26,416
A1 B1 TDF/FTC + DRV/r €10,165 0.727 €13,977 €6674 0.202 €33,061
A1 B1 TDF/FTC + LPV/r €9517 0.715 €13,312 €6026 0.190 €31,793
A1 B1 TDF/FTC + RAL €12,174 0.735 €16,552 €8682 0.210 €41,328
B1 A1 TDF + 3TC + EFV €8211 0.718 €11,438 €4719 0.192 €24,526
B1 A1 ABC/3TC + EFV €8047 0.689 €11,682 €4555 0.163 €27,880
B1 A1 ABC/3TC + ATV/r €9276 0.731 €12,695 €5784 0.205 €28,182
B1 B1 ABC/3TC + LPV/r €9117 0.699 €13,047 €5626 0.173 €32,448
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; FTC, emtricitabine; GL, guidelines; 
ICER, incremental cost-effectiveness ratio; LPV/r, ritonavir-boosted lopinavir; NVP, nevirapine; QALY, quality-adjusted life year; RAL, raltegravir; TDF, tenofovir.
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available in the literature) referring to a short–medium period. 
This is justified by the fact that the evaluation of the benefits 
and costs of a health program needs synthesis tools capable 
of giving a representation of the reality to study which is as 
faithful as possible,30 especially when the effects of the pro-
gram have a time horizon with a long-term impact, or when 
the data sources are not homogenous (ie, they derive from 
administrative records, clinical studies, and meta-analyses). 
It is therefore necessary to use models, such as in the studied 
case, when the clinical trial (1) is incomplete or lacking (in this 
case, the necessary data for the economic evaluation derive 
from different and nonhomogeneous sources) and (2) only 
measures an intermediate result or a short-period follow-up 
(the model can be used to predict the possible final results).
It is worth highlighting, however, that the average cost 
emerging from this present study is substantially in line with 
a recent analysis of the real treatment costs for HIV patients.48 
The research work by Rizzardini et al,48 developed starting 
from the administrative database of the reimbursements of 
the Lombardia region for the years 2004–2007, shows an 
average annual cost per patient of €9609. In this present 
study, the estimated average annual cost per patient is €9270. 
However, the difference between the two annual costs (-4%) 
depends on the fact that the average annual cost considered 
by   Rizzardini et al represents patients in the real clinical 
practice, for instance including patients with hepatitis C virus 
infection and previously treated patients, but taking account 
of all costs during the years 2004 and 2007. With the analy-
sis of naïve patients only, under the same terms used in the 
present analysis, the results of the two research studies would 
certainly converge.
To conclude, it is worth noting that the model developed 
is a dynamic instrument that can be adapted to various health 
care settings (overall in chronic disease, such as hepatitis 
B virus or HIV) in that it can be run using different input data 
(ie, efficacy, cost, and epidemiological data).49 By allowing 
the simulation of different scenarios, it represents an invalu-
able tool for policy makers and health care professionals to 
make short- and long-term cost projections and thus evaluate 
their impact on the available budgets.
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